# Robert W. Baird

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/robert-w-baird
Canonical HTML page: https://getyourbrief.com/entity/robert-w-baird

## Timeline

- **2026-09-01**: Dividend payment — The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
- **2026-08-17**: Ex-dividend date — Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
- **2026-08-08**: Wall Street Zen cuts STAG and ZVIA to Sell — Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
- **2026-08-05**: ZVIA reports Q2 results — Zevia PBC reported EPS of -$0.03, hitting consensus, and revenue of $45.00 million versus a $44.21 million estimate.
- **2026-07-31**: Baird price target and stock rebound — Robert W. Baird set a $66.00 price target; the stock traded up to $57.60, rising $1.79.
- **2026-07-31**: Weiss reiterates buy on STAG; Baird sets $138 target — Weiss Ratings reiterated a buy (b-) rating on Stag Industrial, while Robert W. Baird set a $138.00 target price.
- **2026-07-30**: Q2 2026 earnings release — Middlesex Water reported Q2 EPS of $0.79 on revenue of $56.36 million; shares closed at $55.81, down $1.44.
- **2026-07-28**: STAG reports Q2 earnings miss — Stag Industrial reported EPS of $0.28, missing the consensus estimate of $0.65 by $0.37; revenue was approximately $224 million.
- **2026-07-20**: Weiss Ratings downgrade — Weiss Ratings cut Middlesex Water from 'hold (c)' to 'hold (c-)'.
- **2026-07-17**: Weiss Ratings upgrades ZVIA within sell range — Weiss Ratings raised shares of Zevia PBC from a sell (e+) rating to a sell (d-) rating.
- **2026-07-16**: Barclays raises STAG target but stays Underweight — Barclays boosted its price objective on Stag Industrial from $38.00 to $41.00 and maintained an underweight rating.
- **2026-07-09**: New Street Research target — New Street Research set a $64.00 price target on Middlesex Water.
- **2026-06-26**: BTIG Reiterates Buy with $19 Target — BTIG Research reaffirmed a buy rating and issued a $19.00 price target, representing 107.63% upside.
- **2026-06-13**: Wall Street Zen Downgrades — Wall Street Zen downgraded McGraw Hill from 'buy' to 'hold'.
- **2026-06-12**: Multiple Banks Revise Downward — UBS cut target to $14 (neutral); JPMorgan cut to $20 (overweight); Baird cut to $16 (outperform); Weiss upgraded sell rating to (d) from (d-).

## Recent coverage (14 stories, network-wide)

### STAG Downgraded to Sell as Price Sits 38% Below $50.50 Target
2026-08-13 00:19:12 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen cut Stag Industrial to sell, putting a fresh bearish tilt on a REIT whose shares opened at $36.68 versus a $50.50 consensus target. The same firm also downgraded Zevia PBC as its major shareholder trimmed a 15.87% stake.
Full story: https://getfinancebrief.com/story/stag-industrial-wall-street-zen-sell-downgrade

### ROAD Q3 Earnings Beat by $0.07, Revenue Jumps 28.2% to $999M
2026-08-12 03:18:25 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Construction Partners (ROAD) posted a $0.07 EPS surprise and 28.2% revenue growth, yet analyst downgrades and price target cuts cloud the outlook. The stock's low PEG ratio of 0.85 contrasts with a high debt load and thin margins, creating a complex picture for value and growth investors.
Full story: https://getfinancebrief.com/story/road-q3-2026-earnings-beat-revenue-surge-analyst-downgrades

### ARE Revenue Hits $662.78M But Lab Real Estate Faces Tech Adoption Pressure
2026-08-12 00:15:00 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Alexandria Real Estate Equities reported Q2 revenue of $662.78M, beating estimates, but a sharp EPS miss and cautious analyst outlook raise questions about how PropTech investments in smart labs and energy management will weather a softening biotech leasing market. The REIT’s guidance of $6.35-$6.45 EPS anchors expectations for rent growth and operational efficiency gains.
Full story: https://getproptechbrief.com/story/are-lab-real-estate-proptech-q2-2026

### ARE Stock Rises 3.2% Despite $0.52 EPS Miss: FY26 Guidance Saves the Quarter
2026-08-12 00:14:53 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Alexandria Real Estate Equities shares climbed 3.2% to $53.08 after Q2 revenue of $662.78M beat estimates, even as EPS missed by $0.52. The FY 2026 EPS guidance of $6.35-$6.45 provides a stalwart midpoint against a choppy analyst landscape, while a 5.4% dividend yield offers a cushion for income investors.
Full story: https://getfinancebrief.com/story/are-q2-2026-earnings-stock-rise-guidance

### ARE Q2 Revenue $662.78M: What Biotech Tenants Should Expect from FY’26 Guidance
2026-08-12 00:14:45 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Full story: https://getbiobrief.com/story/alexandria-biotech-tenant-implications-fy26

### HC Wainwright Cuts Circle (CRCL) to $104, Still Sees 64% Upside
2026-08-07 01:20:20 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

HC Wainwright and Needham lowered price targets on Circle Internet Group but maintained Buy ratings as analysts remain split on the stablecoin issuer. The stock trades at $63.48, far below the consensus target of $100.06, highlighting both opportunity and risk.
Full story: https://getfinancebrief.com/story/circle-crcl-price-target-cut-finance

### USDC Issuer Circle (CRCL) Sees Targets Slashed, Yet 100% Upside Possible
2026-08-07 01:20:09 · Sector: crypto · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Two investment banks cut their price targets on Circle Internet Group, the firm behind the USDC stablecoin, citing near-term headwinds—but both maintained Buy ratings with triple-digit upside potential. The stock’s deep pullback from its $189 high reflects broader crypto market caution.
Full story: https://getcryptobrief.com/story/circle-usdc-price-target-crypto

### ServiceTitan’s $100 Target Signals 50% Upside for PropTech Trades Software
2026-08-01 22:19:19 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Needham & Company’s reasserted Buy rating on ServiceTitan, with a $100 price target, underscores the growing confidence in cloud-based platforms that digitize home and commercial service trades. For PropTech investors, the move highlights how essential service management software is becoming within the real estate ecosystem.
Full story: https://getproptechbrief.com/story/servicetitan-needham-buy-rating-proptech-upside

### MSEX Q2 EPS Soars 27% to $0.79, Dividend Yield Holds at 2.5%
2026-08-01 00:15:30 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Middlesex Water's Q2 EPS of $0.79 surged past estimates, reinforcing its reputation as a stable income play. With a 2.5% yield and 60% payout ratio, the utility delivered strong net margins of 22.07%. However, mixed analyst ratings and a beta of 0.78 suggest cautious optimism.
Full story: https://getfinancebrief.com/story/middlesex-water-q2-earnings-beat-eps-dividend

### ResMed Faces $270.64 Consensus Target Amid Analyst Divide on Sleep Device Demand
2026-07-10 14:15:23 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Full story: https://gethealthbrief.com/story/resmed-analyst-target-sleep-apnea-demand

### ResMed Targets Drop to $225 at Wells Fargo; Upside Remains at +23.2%
2026-07-10 14:15:12 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo’s $225 target is the lowest among major banks, yet ResMed’s average analyst target of $270.64 implies a 23.2% upside. Markets weigh defensive balance sheet qualities against emerging therapeutic competition.
Full story: https://getfinancebrief.com/story/resmed-stock-analyst-target-cuts-wells-fargo

### ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets
2026-07-10 14:14:59 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Full story: https://getbiobrief.com/story/resmed-analyst-divide-biotech-investment

### BTIG Sees 108% Upside in McGraw Hill Despite EdTech Reset
2026-06-28 07:38:04 · Sector: edtech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street analyst BTIG reaffirmed a buy rating and $19 target for McGraw Hill (MH), projecting a 107.63% gain from its depressed $9.15 share price. The call highlights deep value in the educational publisher as the entire edtech sector undergoes a post-pandemic correction. With a consensus 'Moderate Buy' and $18.72 target, the stock's extreme undervaluation could reward contrarian edtech investors.
Full story: https://getedtechbrief.com/story/mcgraw-hill-btig-108-percent-upside-edtech

### NVIDIA Eyes GTC 2026 Catalyst Following $180.25 Pre-Conference Pullback
2026-03-15 00:26:20 · Sector: saas · Sentiment: Positive · Impact: 7/10 · Sources: 2

NVIDIA shares dipped to $180.25 on March 13 as investors recalibrated positions ahead of the highly anticipated GTC 2026 conference. Despite the short-term volatility, the company is coming off a record-breaking fiscal 2026 with $215.9 billion in total revenue, driven by insatiable demand for its Blackwell AI architecture.
Full story: https://getsaasbrief.com/story/nvidia-gtc-2026-anticipation-stock-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.